Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt Diag Hld Regulatory News (IDHC)

Share Price Information for Int Diag Hld (IDHC)

Share Price is delayed by 15 minutes
Get Live Data
0.50    0.004 (0.81%)
Bid:
0.49
Ask:
0.502
Spread: 0.012 (2.449%)
Market Cap: $290.66m
IDHC Live PriceLast checked at - London Stock Exchange

Intraday Int Diag Hld Share Chart

Appointment of a Broker

7 Mar 2019 07:00

RNS Number : 0923S
Integrated Diagnostics Holdings PLC
07 March 2019
 

Integrated Diagnostics Holdings Plc

Company Announcement

 

7 March 2019

Appointment of J.P. Morgan Cazenove as Corporate Broker

 

(Cairo and London) - Integrated Diagnostics Holdings ("IDH" or "the Company"), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, announced today that it has appointed J.P. Morgan Cazenove as Corporate Broker.

 

-Ends-

About Integrated Diagnostics Holdings

IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Scan (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 1,400 diagnostics tests. From its base of 405 branches as of 30 June 2018, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern and African markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015.

 

IDH's forward-looking strategy rests on leveraging its established business model to achieve four key strategic goals, namely: (1) continue to expand customer reach; (2) increase the number of tests per patient; (3) expand into new geographic markets through selective, value-accretive acquisitions; and (4) introduce new medical services by leveraging the Group's network and reputable brand position. Learn more at idhcorp.com.

 

Contacts

IDH

+20 (0)2 3345 5530

Sherif El-Ghamrawi, Investor Relations Director

+20 (0)10 0447 8699sherif.elghamrawi@idhcorp.com

 

 

Hudson Sandler (International Media relations)

+44 (0) 207 796 4133

Dan de BelderBertie Berger

idh@hudsonsandler.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
APPSSDFWMFUSEDD
Date   Source Headline
24th Jun 20263:37 pmRNSHolding(s) in Company
24th Jun 20263:19 pmRNSForm 8.3 - INTEGRATED DIAGNOSTICS HOLDINGS PLC
24th Jun 20262:30 pmRNSForm 8 (OPD) - IDH plc - Hena Holdings Ltd
24th Jun 202610:44 amRNSForm 8.3 - Integrated Diagnostic Holdings plc
24th Jun 20269:26 amPRNForm 8.3 - Integrated Diagnostics Holdings plc
23rd Jun 20265:05 pmRNSDirector/PDMR Shareholding
23rd Jun 20265:03 pmRNSHolding(s) in Company
23rd Jun 20263:53 pmRNSStatement re Mandatory Final Cash Offer
23rd Jun 202610:41 amRNSDisclosure Table
23rd Jun 202610:15 amRNSMANDATORY FINAL CASH OFFER
20th May 20262:05 pmRNSReplacement - 1st Quarter Results
20th May 20267:00 amRNS1st Quarter Results
19th May 20265:09 pmRNSResult of AGM
30th Apr 202612:39 pmRNSReplacement - Holding(s) in Company
23rd Apr 20261:06 pmRNSAnnual Financial Report & Notice of AGM
17th Apr 20267:00 amRNSFinal Results
8th Apr 20265:50 pmRNSHolding(s) in Company
8th Apr 20265:49 pmRNSHolding(s) in Company
13th Nov 20257:00 amRNS3rd Quarter Results
7th Nov 20257:00 amRNSNotice of Results
2nd Sep 20257:00 amRNSHalf-year Report
29th Aug 202511:55 amRNSNotice of Results
20th Jun 20257:00 amRNSIDH Strengthens Egyptian Radiology portfolio
28th May 20257:00 amRNS1st Quarter Results
27th May 20255:00 pmRNSResult of AGM
22nd May 20257:00 amRNSNotice of Results
24th Apr 20253:30 pmRNSAnnual Financial Report & Notice of AGM
17th Apr 20257:00 amRNSFinal Results
10th Apr 20254:41 pmRNSNotice of Results
9th Dec 202410:59 amRNSIDH INCREASES STAKE IN BIOLAB KSA
14th Nov 20247:00 amRNS3rd Quarter Results
11th Nov 202411:29 amRNSNotice of Results
8th Oct 20245:21 pmRNSCancellation of Treasury Shares
1st Oct 20249:00 amRNSTotal Voting Rights
18th Sep 20244:14 pmRNSCompletion of Treasury Shares Removal Process
6th Sep 20247:00 amRNSUpdate on Treasury Shares Removal Process
5th Sep 20247:00 amRNSCompletion of EGX Delisting
28th Aug 20247:00 amRNSHalf-year Report
27th Aug 20247:00 amRNSEGX Delisting – buyback under EGX's OPR
23rd Aug 20241:30 pmRNSNotice of Results
13th Aug 20247:00 amRNSEGX Delisting – timeline under EGX's OPR
18th Jul 20243:45 pmRNSResults of Extraordinary General Meeting
1st Jul 20243:40 pmRNSPublication of Circular and Notice of EGM
27th Jun 20247:00 amRNSIDH's proposed revised Delisting Buyback Price
12th Jun 20243:35 pmRNSResults of Extraordinary General Meeting
30th May 20247:00 amRNS1ST QUARTER RESULTS
29th May 20243:44 pmRNSResult of AGM
28th May 202410:42 amRNSNotice of Results
24th May 20244:16 pmRNSPublication of Circular and Notice of EGM
16th May 20247:00 amRNSIDH proposing to delist its shares from the EGX

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.